Lurasidone updated on 06-10-2025

All congenital malformations (majors, minors, majors and minors, or unspecified)

id	Study   Auto Kernizan (Controls exposed to LTG), 2024Kernizan (Controls unexposed, sick), 2024Cohen, 2023	Lib. in paper	Exposition period  Auto during pregnancy (anytime or not specified)1st trimester2nd trimester3rd trimester2nd and/or 3rd trimesterthroughout pregnancyearly pregnancydays before deliverylate pregnancypreconception-onlypericonceptionalpreconceptional for kinetic reasonat least 1st trimester3 months (or more) before pregnancy or during pregnancy1st and 2nd trimester3 months or more before pregnancy or1st trimester	Study type  All studies Case control excluded Only case control	Control type    Auto unexposed (general population or NOS)unexposed, sickunexposed, disease freeexposed to other treatment, sicknot specifiedsiblingwhatever (meta-analysis)	Tags	OR 95%CI	x1/n1 x0/n0	no cases	no exposed	ROB	Ref.
S18402 R77654	Kernizan (Controls exposed to LTG), 2024	Malformations	during pregnancy (anytime or not specified)	retrospective cohort	exposed to other treatment, sick excluded	Adjustment: No	0.16 [0.01;4.14] C excluded (control group)	0/25   1/13	1	25		ref
S18400 R77617	Kernizan (Controls unexposed, sick), 2024	Malformations	during pregnancy (anytime or not specified) excluded	retrospective cohort	unexposed, sick	Adjustment: No	0.28 [0.02;4.94] C excluded (exposition period)	0/25   9/139	9	25		ref
S14429 R57277	Cohen, 2023	Major congenital malformations	1st trimester	prospective cohort	unexposed, sick	Adjustment: Yes	1.32 [0.38;4.61]	3/137   16/904	19	137		ref
					Total	1 studies	1.32 [0.38;4.60]		19	137
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

Sensitivity analysis

Publication bias and p-hacking diagnosis

Sub-groups analysis using all included studies

excluded 18402